Brief: EMA's CHMP Recommended Granting A Marketing Authorisation For Mcombriax
27/02/2026 11:17
Feb 27 (Reuters) - EMA's CHMP: EMA'S CHMP: RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR MCOMBRIAX EMA'S CHMP: COMMITTEE ADOPTED A POSITIVE OPINION FOR RHAPSIDO EMA'S CHMP: COMMITTEE RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR DAYBU (TROFINETIDE) EMA'S CHMP: ILOPERIDONE VANDA PHARMACEUTICALS (ILOPERIDONE) RECEIVED NEGATIVE OPINION FROM CHMP FOR TREATMENT OF SCHIZOPHRENIA EMA'S CHMP: COMMITTEE ADOPTED A POSITIVE OPINION FOR ACOZIBOROLE WINTHROP EMA'S CHMP: COMMITTEE RECOMMENDED TO EXTEND USE OF DUPIXENT (DUPILUMAB), FOR TREATMENT OF CHRONIC SPONTANEOUS URTICARIA IN CHILDREN AGED 2 TO 11 YRS
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'